Global Health Limited (NSE: Medanta, BSE: 543654), one of India’s largest private multi-specialty tertiary care providers in the North and East, today announced its consolidated financial results for the quarter and nine months ended December 31, 2025. For Q3 FY26, consolidated total income grew 19.1% year-on-year to ₹11,428 million. EBITDA excluding the Noida hospital increased 10.9% to ₹2,814 million, with margins of 25.4%. EBITDA including Noida stood at ₹2,494 million, with margins of 21.8%, reflecting initial operating losses at the new facility. Medanta Noida, which commenced operations in September 2025, generated revenue of ₹343 million and reported an EBITDA loss of ₹320 million during the quarter.
Profit after tax for Q3 FY26 was ₹950 million, impacted by depreciation and finance costs related to Noida, initial operating losses, and a non-recurring exceptional expense of ₹366 million due to the statutory implementation of new Labour Codes.
Operational performance remained robust, with inpatient and outpatient volumes rising 14.3% and 19.5%, respectively. ARPOB increased 9.9% to ₹67,361, while 144 beds were added during the quarter.
For 9M FY26, total income rose 17.6% to ₹33,131 million and PAT increased 8.5% to ₹4,124 million, supported by strong growth in developing hospitals, international patient revenue, and OPD pharmacy sales.
